$GENB

2 stories mentioning GENBUpdated just now

Every FINWIRES story that references GENB, newest first.

Generate Biomedicines Shares Fall Following Q2 Financial Results

Generate Biomedicines (GENB) shares fell 4.6% in Thursday trading after the company posted a wider-than-expected Q2 net loss and lower revenue.The company reported Q2 net loss of $0.52 per diluted share, narrowing from a loss of $1.94 a year earlier.Four analysts surveyed by FactSet expected a loss of $0.50.Collaboration revenue for the quarter ended June 30 was $6.3 million, down from $10.1 million a year ago.Three analysts expected $5.5 million.Price: $13.83, Change: $-0.66, Percent Change: -4.55%

$GENB

Research115d ago

HC Wainwright Initiates Generate Biomedicines at Buy With $16 Price Target

Generate Biomedicines (GENB) has an average rating of buy and mean price target of $25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$GENB

Track with the FINWIRES app suite

FolioX

Track GENB in your portfolio

WheelAI

Analyze GENB options with the wheel strategy

StockInsider

See market sentiment on GENB